Welcome to our dedicated page for Elevation Oncolo news (Ticker: ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncolo stock.
Elevation Oncology, Inc. (NASDAQ: ELEV) pioneers precision antibody-drug conjugates (ADCs) targeting Claudin 18.2 and HER3 for solid tumor treatment. This news hub provides investors and researchers with essential updates on clinical developments, financial milestones, and strategic initiatives.
Access real-time announcements about Phase 1 trials for lead candidate EO-3021, preclinical progress of HER3-targeting EO-1022, and partnership agreements shaping the company’s ADC pipeline. Our curated feed eliminates noise by focusing exclusively on material events affecting Elevation Oncology’s trajectory in precision oncology.
Key content categories include clinical trial results, regulatory filings, executive leadership updates, and research collaborations. Bookmark this page to monitor how Elevation Oncology’s targeted ADC approach addresses unmet needs in gastric, gastroesophageal, and other cancers.
Elevation Oncology (Nasdaq: ELEV) announced that the FDA has granted Fast Track designation to EO-3021, a differentiated antibody drug conjugate, for treating advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer expressing Claudin 18.2 that has progressed after prior therapy. This designation is based on nonclinical and initial clinical data from the ongoing Phase 1 trial, which showed a confirmed overall response rate of 42.8% in a Claudin 18.2-enriched subset of GC/GEJ cancer patients. The company observed differentiated tolerability with minimal MMAE-associated toxicities. Elevation Oncology plans to report additional data in the first half of 2025 and initiate the combination portion of the study later this year.
Elevation Oncology (Nasdaq: ELEV), a company focused on developing selective cancer therapies for solid tumors, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Joseph J. Ferra will engage in a fireside chat on Tuesday, September 10, 2024, at 11:30 am ET.
The event will be accessible via a live webcast, with a replay available afterwards. Interested parties can view the webcast on the Events page of Elevation Oncology's Investor Relations website at https://investors.elevationoncology.com. This presentation offers an opportunity for investors and analysts to gain insights into the company's innovative approach to cancer treatment and its future prospects in the oncology sector.
Elevation Oncology (Nasdaq: ELEV) reported promising initial data from its Phase 1 clinical trial of EO-3021, showing a 42.8% confirmed ORR in Claudin 18.2-enriched gastric and GEJ cancer patients. The company is advancing to the dose expansion phase, with additional monotherapy data expected in 1H 2025. Elevation secured agreements with Lilly and GSK to evaluate EO-3021 in combination with ramucirumab and dostarlimab, respectively. The company remains on track to nominate a development candidate for its HER3-ADC program in 2H 2024.
Financially, Elevation reported $110.8 million in cash and equivalents as of June 30, 2024, up from $83.1 million at the end of 2023. Q2 2024 R&D expenses were $6.6 million, while G&A expenses were $4.4 million. The net loss for Q2 2024 was $10.5 million. The company expects its current cash position to fund operations into 2026.
Elevation Oncology (Nasdaq: ELEV) announced promising initial data from the Phase 1 clinical trial of EO-3021 in patients with advanced solid tumors likely to express Claudin 18.2. Key highlights include:
1. 42.8% confirmed objective response rate in Claudin 18.2-enriched gastric and GEJ cancer subset.
2. Differentiated safety profile with minimal MMAE-associated toxicities.
3. Advancing to dose expansion phase; additional monotherapy data expected in 1H 2025.
4. Combination portion of Phase 1 trial to begin by year-end 2024.
The trial showed EO-3021 to be generally well-tolerated with no Grade 4 or 5 treatment-related adverse events. The company plans to explore doses of 2.0 mg/kg and 2.5 mg/kg IV Q3W in the expansion phase.
Elevation Oncology announces plans to expand its Phase 1 clinical trial of EO-3021, targeting advanced gastric or gastroesophageal junction cancer. The trial will now include combination cohorts with ramucirumab (a VEGFR2 inhibitor) and dostarlimab (a PD-1 inhibitor), thanks to clinical supply agreements with Lilly and GSK. Dosing for these combinations is expected to start by the end of 2024.
The company aims to improve treatment outcomes by combining EO-3021 with these agents, potentially offering better safety and efficacy profiles. Initial data from the EO-3021 monotherapy trial is anticipated by mid-Q3 2024, with more data expected in the first half of 2025.
Elevation Oncology, Inc. (Nasdaq: ELEV) will have its CEO, Joseph J. Ferra, participate in a fireside chat at the Citizens JMP Life Sciences Conference on May 14, 2024. The company focuses on developing cancer therapies for solid tumors with unmet medical needs.
Elevation Oncology, Inc. reported its first-quarter 2024 financial results, highlighting recent business achievements. The company raised $44.2 million year-to-date through an ATM facility, extending its cash runway into 2026. Enrollment in the Phase 1 clinical trial of EO-3021 is ongoing in the U.S. and Japan, with initial safety and efficacy data expected by mid-3Q 2024. Preclinical proof-of-concept data for the HER3-ADC program was presented at the AACR Annual Meeting, with the company on track to nominate a development candidate in 2H 2024.
FAQ
What is the current stock price of Elevation Oncolo (ELEV)?
What is the market cap of Elevation Oncolo (ELEV)?
